Convergent evidence suggests that amphetamine (AMPH) exerts its rewarding and locomotor stimulating effects via release of dopamine in the nucleus accumbens. However, there is no consensus as to the relative contributions of core and medial shell subregions to these effects. Moreover, the literature is based primarily on intracranial administration, which cannot fully mimic the drug distribution achieved by systemic administration. In the present study, the effects of bilateral 6-hydroxydopamine lesions of the accumbens core or medial shell on rewarding and locomotor stimulating effects of systemically administered amphetamine (0.75 mg/kg, i.p.) were examined in a conditioned place preference ( 
Introduction
Convergent evidence suggests that the rewarding and behavioral activating effects of psychomotor stimulant drugs are initiated by increased dopaminergic transmission in the nucleus accumbens (NAcc). Evidence is perhaps strongest for the prototypic psychomotor stimulant, amphetamine (AMPH). For example, the locomotor stimulant effect of systemic AMPH is mimicked by intra-accumbens infusion of AMPH or dopamine (DA) (Pijnenburg et al., 1976; Campbell et al., 1997) and is inhibited by intraaccumbens administration of DA antagonists (Pijnenburg et al., 1975; Roberts et al., 1975; Phillips et al., 1994) or 6-hydroxydopamine (6-OHDA) (Kelly et al., 1975; Joyce et al., 1983; Clarke et al., 1988) . Similarly, the rewarding effects of AMPH are either mimicked or inhibited by the same types of manipulations (Yokel and Wise, 1976; Lyness et al., 1979; Spyraki et al., 1982; Carr and White, 1991; Phillips et al., 1994; Izzo et al., 2001) .
The NAcc is a heterogeneous structure, as evinced by immunohistochemical staining and neuronal projection patterns (Zahm and Brog, 1992) . The major subdivisions are a medioventral shell and a dorsolateral core. These subregions are functionally distinct (Maldonado-Irizarry and Kelley, 1995; Weiner et al., 1996; Kelley et al., 1997; Parkinson et al., 1999; Boye et al., 2001; Ikemoto, 2002) , but their precise roles in reward and locomotor activation are uncertain. For example, the locomotor stimulant effect of AMPH has been attributed to an action in the core (Weiner et al., 1996; West et al., 1999; Boye et al., 2001) or in medial shell (Heidbreder and Feldon, 1998; Parkinson et al., 1999) or in both structures (Pierce and Kalivas, 1995; Ikemoto, 2002) . In contrast, certain dopaminergic drugs have been shown to maintain responding when infused into (medial) shell but not core (Carlezon and Wise, 1996; Ikemoto et al., 1997) . Intra-shell self-administration of AMPH has also been reported (Hoebel et al., 1983; Chevrette et al., 2002) , but in these studies intra-core infusions were not examined.
A feature of almost all the behavioral studies using AMPH was that the drug was given directly into the NAcc; after intracranial administration, drug distribution and local concentration differ markedly from that achieved after systemic administration. Recently, we combined systemic AMPH administration with 6-OHDA lesions and found that locomotor stimulation was blunted by dopaminergic denervation of core and not medial shell (Boye et al., 2001 ).
The present study aimed to establish the relative involvement of NAcc core and medial shell subregions in systemic AMPHinduced behavioral activation and reward. Rats that had sustained 6-OHDA lesions of NAcc core or medial shell were assessed for AMPH-induced locomotor activation and conditioned place preference (CPP). To assess the possibility that decreased CPP indicated a deficit not in reward but in learning, memory, or sensory function, morphine CPP was also tested.
Materials and Methods

Subjects
Subjects were 142 male Long-Evans rats (Charles River, St. Constant, Quebec) weighing 270 -310 gm at time of surgery. Rats were housed in groups of three in clear Plexiglas cages in a temperature-and humiditycontrolled animal colony that was lit from 7 A.M. to 7 P.M. Food and water were available ad libitum except during behavioral testing. All experiments were approved by the McGill Faculty of Medicine Animal Care Committee in accordance with Canadian Council on Animal Care guidelines.
Stereotaxic infusion of 6-OHDA
Rats were anesthetized with ketamine HCl (90 mg/kg, i.p.) and xylazine HCl (16 mg/kg, i.p.) 15 min after pretreatment with atropine methyl nitrate (0.05 mg/kg, s.c.). The rat was placed in a stereotaxic apparatus (Kopf, Tujunga, CA) with the incisor bar set at Ϫ3.9 mm. Rats received bilateral infusions of either 6-OHDA or vehicle into either NAcc core or medial shell. Infusions were made via a 30 gauge stainless steel cannula attached by polyethylene tubing to a 10 l Hamilton syringe driven by a model 5000 Micro Injection Unit (Kopf). For greater accuracy, coordinates for both the core and the medial shell were derived from the mean of two coordinate systems. Thus, anterior-posterior coordinates were ϩ10.3 mm from interaural zero and ϩ1.3 mm from bregma for both core and shell. Lateral coordinates were Ϯ0.6 mm (shell) and Ϯ2.4 mm (core). Ventral coordinates for shell (three injections) were ϩ2.0, ϩ2.4, and ϩ2.8 mm from interaural zero and Ϫ8.0, Ϫ7.6, and Ϫ7.2 mm from bregma. Ventral coordinates for core were ϩ2.9 mm from interaural zero and Ϫ7.1 mm from bregma. All coordinates are based on the atlas of Paxinos and Watson (1997) . 6-OHDA or vehicle was infused on each side in a volume of 0.1 l (core) or as three infusions of 0.06 l each (shell) at a rate of 0.1 l/min. The concentration of 6-OHDA used was 80 g/l (core) or 48 g/l (shell). The cannula remained at the final infusion site for 5 min. Dipyrone (100 mg/kg, s.c.) provided analgesia after surgery. Animals were allowed 7-11 d recovery before conditioning (experiments 1 and 3) or testing (experiment 2). Four animals died after surgery in experiment 3.
Conditioned place preference testing
General procedure. The method was modified from that of Vezina and Stewart (1987) . Eight CPP cages [58.1 cm (length) ϫ 28.8 cm (width) ϫ 53.0 cm (height)] were used, each comprising four outer walls made of white plastic-coated particle board (Melamine) and an open top. Cages sat on linoleum flooring covered with a thin layer of Beta Chip bedding. There was no wall dividing the cage into two compartments. Two removable square floor tiles [28.5 cm (length) ϫ 28.5 cm (width) ϫ 5.5 cm (height)] were inserted into each cage; these served as tactile cues. Floor tiles were of two types: mesh and bar. These two textures were provided, respectively, by a stainless steel grid with squares of 1 ϫ 1 cm and by 12 stainless steel bars of 1.2 cm diameter separated by 1.5 cm edge to edge. Both floor types were mounted on square Melamine frames. All behavioral testing was performed in a room lit with a Kodak GBX-2 safelight filter (Vistek, Toronto, Ontario, Canada) providing far-red illumination (wavelength Ͼ650 nm) to minimize visual cues. The location and movements of rats during behavioral testing were monitored by a closed circuit television video camera (Panasonic) linked to a commercial tracking system (EthoVision v3.0, Noldus Information Technology, Leesburg, VA).
Behavioral testing took place over 8 consecutive days and consisted of three phases: preexposure, conditioning, and testing. During all three phases, animals were habituated to the test room in home cages for 15 min before placement into test CPP cages. The preexposure phase served to habituate each animal to the CPP cage itself. This phase comprised a single 20 min session performed in the absence of floor tiles. The conditioning phase took place on days 2-7. It comprised six daily sessions of 45 min each: three sessions with drug and three sessions with saline administration. Drug and saline were administered on alternating days. After injection, each rat was immediately placed in the middle of a CPP cage. During the conditioning trials, rats had access to the entire cage, which provided a single tactile floor cue (either two mesh tiles or two bar tiles).
On the day immediately after the final conditioning trial, a single 10 min test session was given. Here, the CPP cages contained one bar tile and one mesh tile. Animals in a drug-free state were placed in the middle of the cage and given free choice between the half of their cage with the bar texture and that with the mesh texture. Before a new test or conditioning session was started, half of the soiled Beta Chip was removed and replaced with new bedding, and the cage walls and tiles were wiped with 40% ethanol and allowed to dry. Groups of animals were counterbalanced as fully as possible, not only with respect to the texture that was paired with drug but also with respect to the position of that texture within the test cage on test day and the order of drug versus saline administration during conditioning. On the test day, the time spent on each side of the apparatus was recorded. The location of a rat was defined as its center, as determined by the tracking system. During conditioning trials, locomotor activity was recorded as total horizontal distance moved. All testing was done between 8:30 A.M. and 5:30 P.M. A pilot study in which rats received saline paired with both floor textures showed that rats had no significant preference for either texture on test day (our unpublished observations). Thus the procedure can be considered unbiased.
Experimental procedures. In experiment 1, rats received bilateral infusion of 6-OHDA or vehicle into either core or medial shell 7-11 d before preexposure. Rats were then conditioned with 0.75 mg/kg AMPH intraperitoneally. In experiment 2, rats received bilateral 6-OHDA or vehicle infusions into medial shell. Half of the rats in each surgery group received 0.75 mg/kg AMPH intraperitoneally; the other half were conditioned with 10 mg/kg morphine intraperitoneally. Experiment 3 is similar in design to experiment 1 except that rats underwent stereotaxic infusion surgery after conditioning but before testing (Fig. 1 ).
Quantitative [ 125 I]RTI-55 autoradiography
The extent of the 6-OHDA lesion was quantified by autoradiographic labeling of the plasmalemmal DA transporter (DAT) using a nonsaturating concentration of [ 125 I]RTI-55 (2200 Ci/mmol; NEN-Mandel, Guelph, Ontario), because it has been shown previously that percentage loss of DAT accurately represents tissue DA loss (Joyce, 1991a,b) . [
125 I]RTI-55 binds selectively to DAT provided the serotonin transporter (SERT) is inhibited (Boja et al., 1992; Coulter et al., 1995) . Conversely, SERT can be selectively labeled via occlusion of DAT (Pradhan et al., 2002) . The day after CPP testing, rats were anesthetized with sodium pentobarbital (65 mg/kg, i.p.) and decapitated. Brains were removed rapidly and frozen in 2-methylbutane at Ϫ50°C for 30 sec and stored at Ϫ40°C. Coronal sections (20 m) were taken on a cryostat at four rostrocaudal levels through the nucleus accumbens: ϩ11.2, ϩ10.7, ϩ10.2, and ϩ 9.7 mm anterior to interaural zero (Paxinos and Watson, 1997) . At each level, five adjacent sections were collected: four for autoradiography and one for Nissl staining with cresyl violet. Sections were thaw mounted onto gelatin-subbed slides, air dried at room temperature for 20 -30 min, and stored with desiccant at Ϫ40°C.
Sections were thawed at room temperature for 10 min and then placed in a staining dish containing an aqueous buffer solution of 120 mM NaCl, 0.1 M sucrose, 10 mM sodium phosphate buffer, and 10 pM [
125 I]RTI-55. To assay for DAT binding, 50 nM citalopram hydrobromide was used to occlude SERT; nonspecific binding was determined by addition of 10 M GBR 12909. To measure SERT binding, 1 M GBR 12935⅐2HCl was added to occlude DAT; nonspecific binding was determined by addition of 50 nM citalopram HBr (Pradhan et al., 2002) . Slides were incubated at room temperature for 2 hr and then washed three times in cold buffer solution (once for 1 min, twice for 20 min) and for 1 sec in distilled and deionized water. They were then blow dried and placed in an x-ray film cassette. Kodak BioMax MS film (Amersham Biosciences, Baie d'Urfé, Québec) was exposed to slides for 48 hr (DAT) or 120 hr (SERT) with [ 125 I] autoradiographic standards (Amersham Biosciences). Films were then processed with Kodak D19 developer and Kodak GBX fixer (Amersham Biosciences). DAT and SERT binding were quantified using an MCID M4 imaging system (Imaging Research, St. Catherines, Ontario).
Histological examination
Tissue was stained with cresyl violet to assess nonspecific damage, as follows. Sections were thawed at room temperature for 10 min and then placed in 0.5% cresyl violet (Sigma-Aldrich, Oakville, Ontario) in distilled water for 20 min. They were rinsed in 95% ethanol twice for 2 min and then in 100% ethanol three times for 15 sec and were dehydrated in xylene three times for 5 min. Slides were coverslipped with Permount and examined under a light microscope (40 -200ϫ magnification).
Drugs
Drug sources were as follows: morphine sulfate (gift from Sabex 2002 Inc., Boucherville, Quebec); D-amphetamine sulfate (Bureau of Drug Research, Ottawa, Ontario); citalopram HBr (gift from H. Lundbeck A/S); dipyrone (Vetoquinol, Quebec, Quebec); ketamine HCl (Vetalar, Vetrepharm, London, Ontario); xylazine HCl (Anased, Novopharm, Toronto, Ontario); atropine methyl nitrate, 6-OHDA HBr, GBR 12909, and GBR 12935⅐2HCl (Sigma-Aldrich, Oakville, Ontario). All other chemicals were obtained from Fisher Scientific (Montreal, Quebec).
Morphine sulfate and D-amphetamine sulfate were dissolved in sterile 0.9% saline and injected at 1 ml/kg. 6-OHDA HBr was dissolved in sterile 0.9% saline containing 0.3 mg/ml sodium metabisulfite (Sigma-Aldrich) as an antioxidant and protected from light. Both 6-OHDA and vehicle solutions were made to pH 7.3 Ϯ 0.1 with NaOH. Doses of all drugs except 6-OHDA HBr are expressed as the salt. 6-OHDA HBr doses are expressed as free base.
Data analysis
A commercial software program (Systat v10.2, SPSS Inc., Chicago, IL) was used for all data analyses. Locomotor response to AMPH was calculated as the difference of locomotor counts between AMPH and saline conditioning sessions; baseline saline scores were calculated as the mean activity over all three conditioning sessions with saline on test day. CPP magnitude was calculated as the difference between time spent on the drug-paired and vehicle-paired sides. The relationship between locomotor and reward measures versus [
125 I]-RTI-55 labeling was analyzed by multiple linear regression (experiments 1 and 3) or Mann-Whitney U test (experiment 2). Activity scores (experiment 1) were analyzed by ANOVA. A p value of Ͻ0.05 (two-tailed) was considered significant.
Results
Histological and autoradiographic characterization of lesions
Minimal neuronal loss was evident at the site of injection in both vehicle groups and in the core lesioned group in all three experiments. A representative coronal section of the medial shell vehicle-infused group is shown in Figure 2 A. In the medial shell lesioned group, tissue damage was more extensive but was nevertheless confined to 0.3 mm from the infusion site, sparing most of the structure (Fig. 2 B) .
[ Tables 1 and 2 . In all experiments, core lesions were less anatomically selective than shell lesions (Fig.  5) . Pooled across experiments, core 6-OHDA animals showed a mean decrease in DAT binding of 68% in core, 29% in medial shell, 30% in ventral shell, 37% in ventral caudate-putamen, and 30% in olfactory tubercle (OT). In contrast, medial shell-infused 6-OHDA reduced DAT binding in medial shell by 62%, but only by 13, 7, 1, and 12% in core, ventral shell, ventral caudate-putamen, and OT, respectively. SERT binding was virtually unchanged (89 -111% of control) by the 6-OHDA lesions in all three experiments (Tables 1, 2 ). (Fig. 6, legend) . Because lesions were not anatomically specific (Fig. 4) , multiple linear regression analysis was performed to assess contributions of core and shell DA innervation to the AMPH-induced locomotor response. Figure 6 , A and B, shows the relationship between locomotor responses to AMPH during conditioning versus DAT binding in core and medial shell. The locomotor stimulant response was significantly correlated with DAT binding in NAcc core ( p Ͻ 0.01) but not NAcc medial shell ( p Ͼ 0.25) (Fig.  6 A, B) . Conversely, the magnitude of AMPH CPP was significantly correlated with residual DAT in the medial shell ( p Ͻ 0.0001) but not in the core ( p Ͼ 0.5) (Fig. 6C,D) .
NAcc medial shell lesions did not prevent acquisition of a CPP for morphine
In experiment 2, the effects of preconditioning lesions of medial shell were tested in rats conditioned with either morphine (10 mg/kg, i.p.) or AMPH (0.75 mg/kg, i.p.). As in experiment 1, AMPH CPP magnitude was reduced or abolished by medial shell 6-OHDA infusion (lesion vs sham: Mann-Whitney U ϭ 90; p Ͻ 0.02) (Fig. 7) . In contrast, lesioned rats did acquire a morphine CPP, and this was of similar magnitude to that of sham controls (lesion vs sham: Mann-Whitney U ϭ 63; p Ͼ 0.5) (Fig. 7) .
Expression of a conditioned place preference for AMPH was abolished by NAcc medial shell, but not NAcc core, lesions
In experiment 3, lesions were performed after conditioning but before testing. Figure 8 , A and B, shows the relationship between DAT binding in NAcc core or medial shell and the CPP magnitude. Two extreme outliers, as defined by the Systat software, were excluded before data analysis. Multiple linear regression analysis showed that CPP magnitude correlated significantly with residual DAT binding in NAcc medial shell ( p Ͻ 0.0005) but not in NAcc core ( p Ͼ 0.25).
Discussion
Methodological aspects
Dopaminergic denervation in core or medial shell has rarely been achieved with any anatomical selectivity (Boye et al., 2001 ). The present study incorporated several methodological improve- 125 I]RTI-55 binding to DAT in animals from core-lesioned, medial shell-lesioned, and sham-operated groups (experiment 3). Because binding was similar between groups that received vehicle in core and medial shell, the latter group has been omitted. Numbers designate distance anterior to interaural zero (in millimeters). Radioligand binding was obtained at a nonsaturating concentration of radioligand and is expressed as attomol per milligram of tissue. Arrows refer to the core subregion. Arrowheads (pointing upward) refer to the medial shell subregion. In most rats, core 6-OHDA lesions were less anatomically selective than shown here (see Fig. 5 ).
Figure 4. Locations of sampled [
125 I]RTI-55 binding in nucleus accumbens core, medial shell, ventral shell, ventral caudate-putamen, and olfactory tubercle. Each rat was sampled at four anterior-posterior levels. Numbers are distances (in millimeters) anterior to interaural zero. Sampling areas were circles of 0.3 mm diameter. Three samples per side per structure were taken at each level, except for ventral shell, where one sample per side was taken at level 11.2 and two per side at all other levels. Adapted from Paxinos and Watson (1997) .
ments. First, stereotaxic lesion coordinates were improved. Second, multiple infusion sites were used for medial shell lesions. Third, diffusion of 6-OHDA from the infusion site was minimized by administering a high concentration in a small volume. Consequently, core and medial shell DAT binding were largely independent (Pearson r ϭ 0.30), which was not the case in our previous study (Pearson r ϭ 0.84) (Boye et al., 2001 ). In addition, nonspecific tissue damage was reduced by neutralizing the 6-OHDA solution before infusion. Thus, despite the unusually high concentration of 6-OHDA used, Nissl staining and SERT autoradiography revealed minimal nonspecific damage.
The present CPP procedure possesses several attractive features. First, latent inhibition can be avoided during the initial preexposure phase by omitting the conditioned stimuli. Second, rats conditioned with saline on both textures showed no significant preference for either texture on test day (our unpublished observations). Hence, our procedure is balanced and avoids the interpretational difficulties inherent in "biased" procedures (Bardo and Bevins, 2000) . The current study is the first to show an AMPH CPP using solely tactile cues.
Mechanisms of amphetamine-induced locomotor activation
The present findings suggest that after systemic AMPH administration, locomotor stimulation is dependent on transmission in NAcc core and not medial shell. To date, only three published studies have examined this question using systemic rather than intracranial AMPH (Weiner et al., 1996; Parkinson et al., 1999; Boye et al., 2001) . Two of these studies showed that core rather than shell lesions reduced AMPH-induced locomotor activation (Weiner et al., 1996; Boye et al., 2001 ). In contrast, Parkinson et al. (1999) reported that excitotoxic lesions of the NAcc core enhanced locomotor stimulant responses to systemic AMPH, whereas medial shell lesions had the opposite effect. On this basis, these authors attributed a critical role to the shell; however, in the latter study, shell lesions attenuated AMPH locomotion to only a modest extent, and core lesions increased baseline locomotion, complicating the interpretation of drug effects. On balance, therefore, the available evidence suggests that NAcc core plays an important role in the locomotor stimulant effect of systemically administered AMPH.
In the present study, medial shell DA innervation was not related to AMPH locomotor stimulation. In contrast, we previously observed a significant negative correlation ( p Ͻ 0.02), such that DA denervation in the medial shell was associated with greater locomotor responses (Boye et al., 2001 ). This discrepancy may reflect differences in lesions coordinates or functional gradients within each NAcc subregion (Essman et al., 1993; Campbell et al., 1997) .
Other striatal regions, notably ventromedial striatum (Dickson et al., 1994) , OT (Cools, 1986; Ikemoto, 2002) , and anteromedial caudate Smith, 1979, 1980) , have also been implicated in AMPH-induced locomotion. It is doubtful that denervation of ventromedial striatum played a significant role in the present study, because lesions were restricted to the anterior portion, which appears not to contribute to AMPH locomotor activation (Dickson et al., 1994) . On the basis of intracranial infusion studies (Cools, 1986; Ikemoto, 2002) , the OT has been proposed as a key structure mediating the locomotor stimulant effects of AMPH. In contrast, locomotor stimulation after systemic AMPH administration was unaffected by 6-OHDA lesions of OT, despite substantial loss of tissue DA (Clarke et al., 1988) . The anteromedial caudate has been proposed to mediate AMPHinduced locomotion (Fink and Smith, 1979) , but this area was probably spared by our lesions. The ventral shell subregion was partially depleted by our core 6-OHDA infusions and, to our knowledge, has not been studied with respect to AMPH locomotion.
Our 6-OHDA infusions almost certainly destroyed noradrenaline (NA) as well as DA terminals in the ventral striatum (Robbins et al., 1983) . Disruption of noradrenergic transmission tends to inhibit AMPH-induced locomotion (Ogren et al., 1983; Archer et al., 1986; Dickinson et al., 1988; Blanc et al., 1994; Darracq et al., 1998; Harro et al., 2000; Drouin et al., 2002a,b; Auclair et al., 2002) [but see Ventura et al. (2003) ], with the medial prefrontal cortex identified as a potential site of action (Blanc et al., 1994; Darracq et al., 1998) . In contrast, noradrenergic transmission in the NAcc appears not to contribute directly to locomotor stimulation (Pijnenburg et al., 1975; Roberts et al., 1975; Kelly and Iversen, 1976; Joyce et al., 1983) . Thus, our 6-OHDA lesion effects on AMPH-induced locomotor activation probably reflect decreased DA rather than NA transmission.
Mechanisms of AMPH-induced reward
Considerable evidence suggests that AMPH exerts its rewarding effects via DA release in the NAcc (Di Chiara, 1995; Koob et al., 1998), with little if any contribution from NA in this structure (Yokel and Wise, 1975; Roberts et al., 1977) . In the present study, medial shell DA denervation was associated with attenuated AMPH CPP. It is unlikely that neighboring structures contributed to this effect, because they were only slightly denervated (Tables 1, 2) . Moreover, substantial 6-OHDA lesions of OT did not alter a CPP for systemic AMPH (Clarke et al., 1990) . Our findings therefore support a role for NAcc medial shell DA in the rewarding effect of AMPH. This conclusion accords with intracranial self-administration studies using other dopaminergic drugs (Carlezon and Wise, 1996; Ikemoto et al., 1997) .
The inhibition of AMPH CPP caused by preconditioning 6-OHDA lesions could reflect impaired acquisition or expression, or both. It is well established that acquisition and expression of CPP are mediated by different dopaminergic mechanisms White, 1990, 1991a,b; Acquas and Di Chiara, 1994; Bardo et al., 1999) . For example, DA antagonist studies show that DA D1 and D2 receptors are required for acquisition, but only DA D1 receptors are required for expression (Hiroi and White, 1991a,b; Acquas and Di Chiara, 1994; Bardo et al., 1999 ). Because our 6-OHDA lesions presumably impaired transmission at both DA receptor types, both acquisition and expression are likely to be affected.
In the present study, morphine served as a positive control. The finding that morphine CPP was unaffected by medial shell lesions (experiment 2) suggests that lesion-induced reduction of AMPH CPP did not result from impaired sensory, motor, or mnemonic function. The present findings also accord with evidence that morphine CPP occurs via a DA-independent mechanism when drug exposure is minimized (Mackey and van der Kooy, 1985; Bechara and van der Kooy, 1992; Bechara et al., 1992; Nader and van der Kooy, 1997; Laviolette et al., 2002 ). In contrast, 6-OHDA lesions of the NAcc have been found to reduce opiate CPP in nondependent rats (Spyraki et al., 1983; Shippenberg et al., 1993) . Several factors could account for this discrepancy. First, these authors denervated the entire NAcc. It is possible that the NAcc medial shell subregion is neither necessary nor sufficient to mediate opiate reward. Second, although our lesions eliminated AMPH CPP, they may not have decreased DA transmission sufficiently to affect morphine CPP. Third, it is possible that different neural mechanisms underlie morphine CPP depending on whether multiple sensory cues or solely tactile cues are used. 
Dissociation of locomotion and reward
The current findings demonstrate a double dissociation in NAcc core versus shell with regard to AMPH-induced locomotor activation and reward. They extend evidence from other behavioral paradigms that also suggest that locomotion and reward are dissociable (Burns et al., 1993; Robledo et al., 1993; Kelley et al., 1997; Ventura et al., 2003) . Burns et al. (1993) performed lesions of the ventral subiculum or basolateral amygdala and demonstrated a double dissociation of the locomotor stimulation and conditioned reinforcement produced by intra-NAcc AMPH. However, it is not clear whether the lesion affected reward processes or produced a memory or sensory deficit. Robledo et al. (1993) showed that neurotensin administered into the NAcc core decreased the locomotor stimulant effect of cocaine but did not affect intravenous self-administration of the drug. In this study, cocaine was given intraperitoneally in the locomotor tests, making interpretation difficult. Kelley et al. (1997) found that administration of an NMDA receptor antagonist into NAcc core, but not shell, disrupted the acquisition of food-reinforced responding without affecting spontaneous locomotor activity. However, this study did not examine the effects of psychostimulants. Last, Ventura et al. (2003) demonstrated that in mice, NA-depleting lesions of the medial prefrontal cortex blocked both AMPHinduced NAcc DA release and CPP while preserving the locomotor stimulant response. It would be interesting to determine whether core and medial shell DA release are differentially affected by these lesions and whether this result extends to rats.
In conclusion, the present study provides the first clear anatomical dissociation between the rewarding and locomotoractivating effects of the prototypic psychostimulant drug AMPH in rats. These acute behavioral effects were mapped onto NAcc medial shell and core, respectively. The experimental approach used here should help to further define mechanisms underlying acute and chronic behavioral effects of other drugs of abuse. Finally, the present core/shell dissociation may be relevant to the role of DA in reward anticipation versus consumption (Wise, 2002) , incentive salience (Berridge and Robinson, 1998) , and other forms of learning (Redgrave et al., 1999; Schultz, 2002) .
